http://www.advfn.com/nasdaq/rss.asp?symbol=ARIA Ariad Company Newsfeed en Fri, 26 Apr 2013 09:42:31 EDT Fri, 26 Apr 2013 09:42:31 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=57339790&headline=as-biotechnology-stocks-soar-bubble-talk-percolates http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=57339790&headline=as-biotechnology-stocks-soar-bubble-talk-percolates <div class='newsbody'><pre> By Joseph Walker </pre> <p> Biotechnology stocks are quite healthy right now, but some think they are due for a cold. </p> <p> The sector is on a run not seen since the go-go days of the late 1990s, bolstered by a string of clinical and regulatory successes that analysts say... Fri, 26 Apr 2013 09:42:31 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=55982237&headline=ariads-15-3-million-share-offering-prices-at-1-3-discount http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=55982237&headline=ariads-15-3-million-share-offering-prices-at-1-3-discount <div class='newsbody'><p> Ariad Pharmaceuticals Inc. (ARIA) said its 15.3 million share offering priced at 1.3% discount to Wednesday's close. </p> <p> Shares fell 2.2% to $19.42 in recent trading, below the offer price of $19.60 a share. The stock has risen 34% in the past 12 months. </p> <p> The company... Thu, 24 Jan 2013 10:40:12 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=55980067&headline=u-s-hot-stock-futures-hot-stocks-to-watch http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=55980067&headline=u-s-hot-stock-futures-hot-stocks-to-watch <div class='newsbody'><p> Among the companies with shares expected to actively trade in Thursday's session are Netflix Inc. (NFLX), Apple Inc. (AAPL) and Mellanox Technologies Ltd. (MLNX, MLNX.TV). </p> <p> Netflix capped a turbulent year by posting a surprise fourth-quarter profit and adding more Internet... Thu, 24 Jan 2013 09:08:15 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=55472553&headline=fda-approves-iclusig-to-treat-two-rare-types-of-leukemia http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=55472553&headline=fda-approves-iclusig-to-treat-two-rare-types-of-leukemia <div class='newsbody'><pre> By Debbie Cai </pre> <p> The U.S. Food and Drug Administration has given advance approval for Iclusig, a drug that treats adults with two rare blood and bone marrow diseases. </p> <p> Iclusig, or ponatinib, was approved more than three months ahead of schedule and is for treating... Fri, 14 Dec 2012 13:02:22 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=52666969&headline=fda-rejects-mercks-treatment-for-bone-cancer http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=52666969&headline=fda-rejects-mercks-treatment-for-bone-cancer <div class='newsbody'><pre> By Tess Stynes </pre> <p> Merck &amp; Co. (MRK) said the U.S. Food and Drug Administration has rejected its new drug application for an investigational maintenance treatment for patients with metastatic soft tissue or bone sarcoma. </p> <p> The pharmaceutical giant said it... Tue, 05 Jun 2012 17:29:32 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=51705616&headline=fda-panel-rejects-proposed-merck-cancer-drug-for-sarcoma-patients http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=51705616&headline=fda-panel-rejects-proposed-merck-cancer-drug-for-sarcoma-patients <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- A federal advisory panel Tuesday rejected an experimental Merck &amp; Co. (MRK) drug for use in patients with soft-tissue or bone sarcomas on concerns it didn't work well enough to offset... Tue, 20 Mar 2012 17:15:23 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=51656390&headline=fda-panel-to-review-merck-glaxo-drugs-for-soft-tissue-sarcoma http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=51656390&headline=fda-panel-to-review-merck-glaxo-drugs-for-soft-tissue-sarcoma <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- The Food and Drug Administration on Friday questioned whether the benefit of using Merck &amp; Co.'s (MRK) experimental cancer drug ridaforolimus in patients with soft-tissue or bone sarcomas... Fri, 16 Mar 2012 09:54:22 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=50439396&headline=ariad-pharmaceuticals-21-5-million-share-offering-priced-at-wednesday http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=50439396&headline=ariad-pharmaceuticals-21-5-million-share-offering-priced-at-wednesday <div class='newsbody'><pre> DOW JONES NEWSWIRES </pre> <p> Ariad Pharmaceuticals Inc.'s (ARIA) offering of 21.5 million shares was priced at Wednesday's close. </p> <p> Shares were trading up 3.5% at $10.78, above the offer and close price of $10.42. The stock has more than doubled this year. As of Oct... Thu, 15 Dec 2011 10:46:30 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=49164041&headline=q-a-living-large-with-stocks-under-10-by-johanna-bennett http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=49164041&headline=q-a-living-large-with-stocks-under-10-by-johanna-bennett <div class='newsbody'><p> Former Wall Street pro Hilary Kramer has literally written the book on investing in small, low-priced stocks. </p> <p> This summer's stock market sell-off hit small-cap stocks hard. But the 47-year-old newsletter editor for publications such as GameChanger Stocks and High Octane... Tue, 13 Sep 2011 22:29:37 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=47755369&headline=cancer-data-deluge-ripples-through-biotech-stocks http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=47755369&headline=cancer-data-deluge-ripples-through-biotech-stocks <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Drug makers like Onyx Pharmaceuticals Inc. (ONXX), Ariad Pharmaceuticals Inc. (ARIA) and Incycte Corp. (INCY) are moving Thursday after the American Society of Clinical Oncology disclosed data on more... Thu, 19 May 2011 12:34:34 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=47741597&headline=astrazeneca-exelixis-cancer-drugs-show-promise-amid-slew-of http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=47741597&headline=astrazeneca-exelixis-cancer-drugs-show-promise-amid-slew-of <div class='newsbody'><pre> By Peter Loftus and Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> An experimental AstraZeneca PLC (AZN) drug delayed death or the return of tumor growth in women with serious ovarian cancer by nearly four months, when compared with a placebo, a new clinical trial found. </p> <p>... Wed, 18 May 2011 18:31:11 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=46064282&headline=ariad-shares-rally-on-positive-results-for-cancer-drug http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=46064282&headline=ariad-shares-rally-on-positive-results-for-cancer-drug <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Ariad Pharmaceuticals Inc. (ARIA) said its experimental treatment for metastatic soft-tissue and bone sarcomas met its primary goal in a late-stage study. </p> <p> Shares jumped 32% to $6.95 in premarket trading, about a five-year high. Through the... Tue, 18 Jan 2011 09:11:34 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=42667570&headline=merck-pays-ariad-to-take-control-of-possible-cancer-treatment http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=42667570&headline=merck-pays-ariad-to-take-control-of-possible-cancer-treatment <div class='newsbody'><pre> DOW JONES NEWSWIRES </pre> <p> Merck &amp; Co. (MRK) and Ariad Pharmaceuticals Inc. (ARIA) said they have restructured their collaboration related to the treatment ridaforolimus, which is currently being evaluated for multiple types of cancer. </p> <p> Under the agreement... Wed, 05 May 2010 07:26:29 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=42069846&headline=us-appeals-court-again-rules-for-lilly-in-ariad-patent-case http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=42069846&headline=us-appeals-court-again-rules-for-lilly-in-ariad-patent-case <div class='newsbody'><pre> By Brent Kendall Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- A federal appeals court on Monday decided for a second time to toss out a $65 million ruling for Ariad Pharmaceuticals Inc. (ARIA) in a patent dispute with Eli Lilly &amp; Co. (LLY). </p> <p> The case... Mon, 22 Mar 2010 12:00:31 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=41766934&headline=ariad-cancer-drug-received-orphan-drug-designation-shares-up http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ARIA&article=41766934&headline=ariad-cancer-drug-received-orphan-drug-designation-shares-up <div class='newsbody'><pre> DOW JONES NEWSWIRES </pre> <p> Ariad Pharmaceuticals Inc. (ARIA) announced its oncology inhibitor received orphan drug designation by both the U.S. and European drug regulators. </p> <p> Shares rose 10.6% premarket to $2.81. </p> <p> Orphan-drug designation is intended to... Mon, 01 Mar 2010 08:53:05 EST